Clinical–Genomic Risk Discordance in Early HR+/HER2− Breast Cancer: A Real-World Cohort from Japan Demonstrates Treatment Impact of Oncotype DX

Clinical-genomic discordance was common. RS reflected tumor biology rather than nodal status, and chemotherapy use depended more on genomic-clinical concordance than CR alone. Integration of clinical and genomic risk is essential for optimizing adjuvant strategies in early HR+/HER2- breast cancer.

Authors

Chika Watanabe (ORCID: https://orcid.org/0000-0003-4905-3798)
Hanae Matsuda
Mariko Nishikawa (ORCID: https://orcid.org/0000-0001-9976-688X)
Masatsune SHIBUTANI
Haruhito Kinoshita
Saeko Henmi
SHINICHIRO KASHIWAGI
TAMAMI MORISAKI
YUKIE TAUCHI
KOJI TAKADA
KANA OGISAWA

Institutions

Osaka Metropolitan University (JP)

Publication Details

Journal: Anticancer Research
Published: 2025-12-30
DOI: https://doi.org/10.21873/anticanres.17957
Primary Topic: Breast Cancer Treatment Studies
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Clinical–Genomic Risk Discordance in Early HR+/HER2− Breast Cancer: A Real-World Cohort from Japan Demonstrates Treatment Impact of Oncotype DX

Chika Watanabe, Hanae Matsuda, Mariko Nishikawa, Masatsune SHIBUTANI et al.

Dec 30, 2025

Anticancer Research

Breast Cancer Treatment Studies

article

Clinical–Genomic Risk Discordance in Early HR+/HER2− Breast Cancer: A Real-World Cohort from Japan Demonstrates Treatment Impact of Oncotype DX

Chika Watanabe, Hanae Matsuda, Mariko Nishikawa, Masatsune SHIBUTANI, Haruhito Kinoshita, Saeko Henmi, SHINICHIRO KASHIWAGI, TAMAMI MORISAKI, YUKIE TAUCHI, KOJI TAKADA, KANA OGISAWA

December 30, 2025article en

Abstract

Clinical-genomic discordance was common. RS reflected tumor biology rather than nodal status, and chemotherapy use depended more on genomic-clinical concordance than CR alone. Integration of clinical and genomic risk is essential for optimizing adjuvant strategies in early HR+/HER2- breast cancer.

Anticancer ResearchVol. 46(1)

Osaka Metropolitan University (JP)

Good health and well-being

Openalex Percentile: Top 33%

Breast Cancer Treatment Studies

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.